VAISHALI
Vaishali Pharma Limited
Vaishali Pharma Limited (VAISHALI) financial statements and selected valuation metrics through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
vaishalipharma.com(opens the company website in a new tab)Key metrics
Price as of 2026-10-16
Full years shown; sign in free for the trailing twelve months. Learn about these metrics →
Price & valuation
Share price and valuation multiples (P/E, P/B and more) over time.
Loading price history…
Compare with peers
Loading peers…
What you need to know
Vaishali Pharma, based in Mumbai, is a pharmaceutical company.
Company snapshot
113thBy market cap
Ranked among 119 companies in Pharmaceuticals.
What we see
- ✓Debt-to-equity of 0.27x — the company is largely funded by its own money, not borrowed funds.
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Sales | 33 Cr | 25 Cr | 27 Cr | 23 Cr |
| Operating expenses (approx.) | 32 Cr | 23 Cr | 27 Cr | 21 Cr |
| EBITDA | 1 Cr | 2 Cr | -0.20 Cr | 1 Cr |
| OPM % | 4.2% | 6.3% | -0.8% | 6.5% |
| Other income | 0.84 Cr | 0.89 Cr | 1 Cr | 0.58 Cr |
| Interest | 0.40 Cr | 0.51 Cr | 0.72 Cr | 0.20 Cr |
| Depreciation | 0.17 Cr | 0.13 Cr | 0.16 Cr | 0.14 Cr |
| Profit before tax | 2 Cr | 2 Cr | 0.29 Cr | 2 Cr |
| Tax % | 28.4% | 28.1% | -29.5% | 13.6% |
| Net profit | 1 Cr | 1 Cr | 0.38 Cr | 2 Cr |
| EPS (₹) | ₹0.09 | ₹0.10 | ₹0.03 | ₹0.12 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2026 | TTM |
|---|---|---|
| Sales | 109 Cr | Sign in free for the trailing twelve months |
| Operating expenses (approx.) | 105 Cr | Sign in free for the trailing twelve months |
| EBITDA | 4 Cr | Sign in free for the trailing twelve months |
| OPM % | 3.8% | Sign in free for the trailing twelve months |
| Other income | 4 Cr | Sign in free for the trailing twelve months |
| Interest | 2 Cr | Sign in free for the trailing twelve months |
| Depreciation | 0.60 Cr | Sign in free for the trailing twelve months |
| Profit before tax | 6 Cr | Sign in free for the trailing twelve months |
| Tax % | 24.6% | Sign in free for the trailing twelve months |
| Net profit | 4 Cr | Sign in free for the trailing twelve months |
| EPS (₹) | ₹0.32 | Sign in free for the trailing twelve months |
| Dividend payout % | — | Sign in free for the trailing twelve months |
The latest four quarters added up, next to each full year
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2026 |
|---|---|
| Equity capital | 26 Cr |
| Reserves | 43 Cr |
| Borrowings | 19 Cr |
| Other liabilities | 36 Cr |
| Total liabilities | 123 Cr |
| Fixed assets (net) | 0.90 Cr |
| CWIP | 0.25 Cr |
| Investments | 6 Cr |
| Inventories | 3 Cr |
| Trade receivables | 51 Cr |
| Cash & bank | 1 Cr |
| Other assets | 61 Cr |
| Total assets | 123 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2026 |
|---|---|
| Cash from operating activity | — |
| Cash from investing | — |
| Cash from financing | — |
| Net cash flow | — |
| Free cash flow (OCF − Capex) | — |
Ratios
| Metric | Mar 2026 |
|---|---|
| ROCE % | 8.5% |
| ROE % | 6.0% |
| Debtor days | 170 |
| Inventory days | 11 |
| Days payable | 71 |
| Cash conversion cycle | 110 |
| Debt / equity | 0.27 |
| Current ratio | 2.34 |
| Net debt / EBITDA | 4.23 |